FDA-cleared profile

GyriCalc (Version 1.0.0)

NeuroSpectrum Insights Corp. · MRI · FDA-cleared (510(k))

Authorized purpose: Adjunctive quantitative brain-mapping report for qualified clinical interpretation of children 24-36 months, providing regional volume, surface-area and local-gyrification measures from 3D T1 MRI.

Clinical role
Automated brain-mapping and quantitative reporting aid; it is not a primary image-review or diagnostic system.
Images and patients
MRI · Brain
Key limitation
Keep in mind: GyriCalc is not intended for primary image review, lesion visualization or lesion quantification, emergency use, diagnosis or aid in diagnosis, and the cleared age range is 24-36 months. Results require qualified clinical interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Adjunctive quantitative brain-mapping report for qualified clinical interpretation of children 24-36 months, providing regional volume, surface-area and local-gyrification measures from 3D T1 MRI.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: 3D T1-weighted DICOM brain MRI acquired at 1.5T or 3T; the ideal isotropic resolution and slice thickness are 1 mm.
  • Who uses it?Intended users: Qualified healthcare professionals and clinicians interpreting pediatric brain MRI.
  • What does the software produce?Output: Automatic labels, visualizations and quantitative measures for brain-structure volume, surface area and local gyrification index, delivered as a PDF report.
  • What is its most important limitation?Key limitation: GyriCalc is not intended for primary image review, lesion visualization or lesion quantification, emergency use, diagnosis or aid in diagnosis, and the cleared age range is 24-36 months. Results require qualified clinical interpretation.

Clinical takeaway. Clinical role: Adjunctive quantitative brain-mapping report for qualified clinical interpretation of children 24-36 months, providing regional volume, surface-area and local-gyrification measures from 3D T1 MRI.

Evidence takeaway. Evidence from the reviewed source record: The FDA-described independent test used 82 T1 MRI studies from 82 children aged 24-36 months, with six experts providing reference segmentations. Average Dice was 0.95. Reported volume MAE ranged from 0.45% to 12.1%, surface-area MAE from 0.33% to 12.6%, and gyrification error from 0.04% to 0.89%; the source identifies several regions exceeding 10% volume or surface-area error.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Adjunctive quantitative brain-mapping report for qualified clinical interpretation of children 24-36 months, providing regional volume, surface-area and local-gyrification measures from 3D T1 MRI.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Automated brain-mapping and quantitative reporting aid; it is not a primary image-review or diagnostic system.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
3D T1-weighted DICOM brain MRI acquired at 1.5T or 3T; the ideal isotropic resolution and slice thickness are 1 mm.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Automatic labels, visualizations and quantitative measures for brain-structure volume, surface area and local gyrification index, delivered as a PDF report.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Pediatric neuroimaging services for children 24-36 months.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Qualified healthcare professionals and clinicians interpreting pediatric brain MRI.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
GyriCalc is not intended for primary image review, lesion visualization or lesion quantification, emergency use, diagnosis or aid in diagnosis, and the cleared age range is 24-36 months. Results require qualified clinical interpretation.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The FDA-described independent test used 82 T1 MRI studies from 82 children aged 24-36 months, with six experts providing reference segmentations. Average Dice was 0.95. Reported volume MAE ranged from 0.45% to 12.1%, surface-area MAE from 0.33% to 12.6%, and gyrification error from 0.04% to 0.89%; the source identifies several regions exceeding 10% volume or surface-area error.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA-described independent test used 82 T1 MRI studies from 82 children aged 24-36 months, with six experts providing reference segmentations. Average Dice was 0.95. Reported volume MAE ranged from 0.45% to 12.1%, surface-area MAE from 0.33% to 12.6%, and gyrification error from 0.04% to 0.89%; the source identifies several regions exceeding 10% volume or surface-area error.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The cleared endpoints are segmentation and quantitative agreement measures, not disease-detection sensitivity.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The cleared endpoints are segmentation and quantitative agreement measures, not disease-detection specificity.

Segmentation Dice

0.95 Dice coefficient, average

  • EndpointSegmentation overlap
  • Population82 independent 3D T1 MRI studies from children aged 24-36 months
  • Tested versionGyriCalc 1.0.0 configuration submitted in K250686

Volume MAE lower bound

0.45 percent absolute error, lower endpoint of reported range

  • EndpointRegional volume mean absolute error
  • Population82 independent 3D T1 MRI studies from children aged 24-36 months
  • Tested versionGyriCalc 1.0.0 configuration submitted in K250686

Volume MAE upper bound

12.1 percent absolute error, upper endpoint of reported range

  • EndpointRegional volume mean absolute error
  • Population82 independent 3D T1 MRI studies from children aged 24-36 months
  • Tested versionGyriCalc 1.0.0 configuration submitted in K250686

Surface-area MAE lower bound

0.33 percent absolute error, lower endpoint of reported range

  • EndpointRegional surface-area mean absolute error
  • Population82 independent 3D T1 MRI studies from children aged 24-36 months
  • Tested versionGyriCalc 1.0.0 configuration submitted in K250686

Surface-area MAE upper bound

12.6 percent absolute error, upper endpoint of reported range

  • EndpointRegional surface-area mean absolute error
  • Population82 independent 3D T1 MRI studies from children aged 24-36 months
  • Tested versionGyriCalc 1.0.0 configuration submitted in K250686

Gyrification error lower bound

0.04 percent error, lower endpoint of reported range

  • EndpointLocal gyrification index error
  • Population82 independent 3D T1 MRI studies from children aged 24-36 months
  • Tested versionGyriCalc 1.0.0 configuration submitted in K250686

Gyrification error upper bound

0.89 percent error, upper endpoint of reported range

  • EndpointLocal gyrification index error
  • Population82 independent 3D T1 MRI studies from children aged 24-36 months
  • Tested versionGyriCalc 1.0.0 configuration submitted in K250686

GyriCalc 1.0.0 pediatric brain-mapping validation

  • DesignIndependent segmentation and quantitative agreement study with six experts in two groups of three and STAPLE reference generation
  • Population82 independent normal-appearing 3D T1 MRI studies from children aged 24-36 months: 54 U.S. and 28 Brazil; 67 at 1.5T and 15 at 3T; Philips 25, GE 56 and Siemens 1
  • Scopeexact submission
  • Tested versionGyriCalc 1.0.0 configuration submitted in K250686
  • Samplen=82
  • IndependenceSponsor or vendor study

K250686

FDA reports average Dice 0.95, volume MAE 0.45%-12.1%, surface-area MAE 0.33%-12.6% and gyrification error 0.04%-0.89%. Several regional volume/surface values exceeded 10%; no averaging is added here.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.

Public pricing
A public SEC filing describes a predetermined per-patient list price for GyriCalc report generation and delivery, but does not disclose the dollar amount, terms or current availability.
  • Exact product version
  • Checked 2026-09-06

This is a commercialization-plan statement, not a current quote or reimbursement amount.

Pricing model
A public SEC filing describes a predetermined per-patient list price for report generation and delivery, but does not disclose the dollar amount, terms or current availability.
  • Exact product version
  • Checked 2026-09-06

This is a commercialization-plan statement, not a current quote or reimbursement amount.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: 3D T1-weighted DICOM brain MRI acquired at 1.5T or 3T; the ideal isotropic resolution and slice thickness are 1 mm.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K250686: GyriCalc

  2. Routing

    Source context, not route validation: The FDA submission describes DICOM MRI input and PDF report output; public buyer material describes a processing-center workflow, while local DICOM routing and report delivery require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K250686: GyriCalc

  3. AI processing

    Source context, not route validation: The reviewed public filing describes completed MRI studies being sent to a NeuroSpectrum Insights processing center and a PDF report being delivered to the ordering clinician.

    Scope: Product family. The filing describes the company's planned commercialization workflow and does not establish current availability or a site-specific service commitment.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-06 · NeuroSpectrum Insights commercialization filing (GyriCalc)

  4. Returned objects

    Source context, not route validation: Automatic labels, visualizations and quantitative measures for brain-structure volume, surface area and local gyrification index, delivered as a PDF report.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K250686: GyriCalc

  5. Viewer/worklist/report

    Unresolved route: Automatic labels, visualizations and quantitative measures for brain-structure volume, surface area and local gyrification index, delivered as a PDF report.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K250686: GyriCalc

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The reviewed public filing describes completed MRI studies being sent to a NeuroSpectrum Insights processing center and a PDF report being delivered to the ordering clinician.
  • Product family
  • Checked 2026-09-06

The filing describes the company's planned commercialization workflow and does not establish current availability or a site-specific service commitment.

Integration
The FDA submission describes DICOM MRI input and PDF report output; public buyer material describes a processing-center workflow, while local DICOM routing and report delivery require confirmation.
  • Exact FDA submission
  • Checked 2026-09-07

PDF brain-mapping report

The cleared product produces a PDF report with regional volume, surface-area and local-gyrification measures.

exact submission · checked 2026-09-07

Processing-center report workflow

The public commercialization filing describes an ordering clinician sending a completed MRI to a NeuroSpectrum Insights processing center and receiving a PDF report.

product family · checked 2026-09-06

The filing describes a planned workflow and does not establish current availability, turnaround, contract terms or security controls.

Artifact correction and standardized reporting

The official GyriCalc page describes correction for motion, intensity inhomogeneity and other artifacts, segmentation of cortical regions, and standardized qualitative/quantitative reporting.

exact product version · checked 2026-09-06
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K250686
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-07-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
23Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, sec filing, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "GyriCalc NeuroSpectrum reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    The reviewed product page and filing do not establish exact-release security controls, retention or assurance documentation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K250686: GyriCalc

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, reportedSensitivity, reportedSpecificity, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. GyriCalc (Version 1.0.0) model card (K250686)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. GyriCalc - Innovative Brain Mapping and Analysis Technology

    NeuroSpectrum Insights - Accessed 2026-09-06

    Scope: clinicalUse, output, limitations, implementationCapabilities

  8. NeuroSpectrum Insights commercialization filing (GyriCalc)

    U.S. Securities and Exchange Commission - Accessed 2026-09-06

    Scope: economics, implementationCapabilities

Research history

  1. K250686 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history